- Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
- Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
- Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
- Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
- Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
- Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
- Matinas BioPharma to Present at Biotech Showcase 2024
- Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
- Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
- Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
More ▼
Key statistics
On Thursday, Matinas BioPharma Holdings Inc (MTNB:ASQ) closed at 0.271, 145.69% above the 52 week low of 0.1103 set on Aug 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.2801 |
---|---|
High | 0.2866 |
Low | 0.271 |
Bid | 0.2721 |
Offer | 0.2723 |
Previous close | 0.2899 |
Average volume | 3.46m |
---|---|
Shares outstanding | 217.26m |
Free float | 210.71m |
P/E (TTM) | -- |
Market cap | 58.88m USD |
EPS (TTM) | -0.0979 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.
More ▼